NRx completes 3 ketamine manufacturing validation batches, awaits US approval
Key Facts
NRx Pharmaceuticals announced the completion of 3 process validation batches of preservative-free ketamine under commercial conditions, a step toward securing the regulatory approval needed to begin supply. In its announcement, the company said it had inventory available for commercial release but was still awaiting approval of its generic drug application. Its chief executive identified Nephron Pharmaceuticals in West Columbia, South Carolina, as its manufacturing partner. The progress comes as the chief executive said US ketamine supplies had relied primarily on overseas manufacturing. He added that hospitals and physicians had faced recurring supply shortages.
Alongside the completion of the manufacturing validation batches, the company announced that it had finished analyzing real-time stability data covering 2 years of storage of preservative-free ketamine at room temperature. It said testing showed "no degradation in purity, potency or sterility" during that period. These results were achieved without adding preservatives to the formulation, according to its statement. The company believes the stability results are consistent with a labeled shelf life of 3 years or more. That duration remains the company's estimate of what the results could support, while the reported real-time testing covers the shorter storage period.
NRx previously said, in an update on the preliminary review of its generic drug application, that the US Food and Drug Administration had identified no substantive deficiencies relating to the drug product or its components. According to the company, this included the proposed labeling and the formulation's chemistry, manufacturing and controls. The remaining issue concerned demonstrating the performance of the vial's Luer-lock tip when connected to a syringe to administer the drug. That issue was classified under the container closure system, according to the company's account of the preliminary regulatory review. The company added that the agency had not requested new clinical, safety, efficacy or drug data to approve the generic drug application.
The product is being reviewed under the generic drug application pathway, which, according to the US Food and Drug Administration, relies on its previous finding that an approved drug is safe and effective. The agency explains that applicants under this pathway are not required to provide independent evidence of the proposed generic drug's safety and efficacy. The agency says approved ketamine injections are used for general anesthesia. In its regulatory clarification, it stresses that "ketamine is not approved for the treatment of any psychiatric disorder." As part of its central nervous system disorders program, NRx is also developing its formulation known as NRX-100, a preservative-free intravenous ketamine.
As part of the drug labeling review, the company announced that it had received a letter from the Food and Drug Administration requesting changes it described as "minor" to the submitted labeling for preservative-free ketamine. According to the company's announcement, the letter addressed the labeling it had submitted as part of the formulation's review process. The agency also requested labeling mock-ups bearing the product's proposed brand name. NRx said that name remained under review by the US agency. Approval of the proposed brand name therefore remains part of the regulatory process the company is awaiting before launching the product under that name.
The company is now working toward a target application review date of 10 November 2026 under the Generic Drug User Fee Act, according to its regulatory update. That date had already been announced in the September update, before the announcement that manufacturing validation batches had been completed. The company said the agency had reclassified the amendment concerning the drug vial from major to minor. It attributed the revised review date to the fact that processing the reclassified amendment "would not require a significant expenditure of FDA resources." The date of 10 November 2026 is a target for regulatory review, while supply of the commercial inventory remains conditional on approval of the application.